文献速递重症综合管理与镇静镇痛

挥发性麻醉药:ICU从业者药理学、给药系统与安全性综合综述

Volatile Anesthetics: A Comprehensive Review of Pharmacology, Delivery Systems, and Safety Considerations for ICU Practitioners.
PubMed 文献 · Crit Care Med · 2026-01-16
一句话结论挥发性麻醉药可作为ICU镇静剂使用,本综述描述其药理学、安全性和微型挥发器给药系统的结构与功能。

本综述通过检索PubMed和MEDLINE数据库,纳入关于成人ICU患者挥发性麻醉药安全性和有效性的原始研究、综述、评论及指南,按药理学特性、给药系统和安全域总结关键发现。挥发性麻醉药为卤代烃,其中枢神经系统为主要作用部位,以呼出气末麻醉药浓度监测临床效应(如对伤害性刺激的不动反应);其药代动力学独特、代谢极少、恢复特征独特,最令人担忧但罕见的并发症为恶性高热。国际上有两种吸入镇静给药系统,均含微型挥发器、输送控制器和监测器,各有安全考量(如潮气量限制),其中一个系统目前正在美国接受评估。结论认为挥发性麻醉药可用作ICU镇静剂。

要点

  • 挥发性麻醉药可用作ICU镇静剂,具有起效和消退迅速、全身代谢极少及恢复特征良好的药理学优势。
  • 以呼出气末麻醉药浓度监测临床效应,如对伤害性刺激的不动反应。
  • 恶性高热是挥发性麻醉药最令人担忧但罕见的并发症。
  • 国际上有两种吸入镇静给药系统,均由微型挥发器、输送控制器和监测器组成,各有安全考量(如潮气量限制)。
  • 其中一个给药系统目前正在美国接受评估。

适用人群与场景

  • 成人ICU患者(纳入文献针对成人ICU患者的安全、疗效和使用)。

红旗征与不能漏的情况

  • 恶性高热是挥发性麻醉药最令人担忧但罕见的并发症。

研究设计与关键结果

  • 综述纳入PubMed和MEDLINE数据库中关于成人ICU患者挥发性麻醉药安全性、有效性和使用的原始研究、综述、评论及指南,由作者审阅并按药理学特性、给药系统和安全域总结关键发现。
  • 挥发性麻醉药为卤代烃,作用机制尚未完全明确,中枢神经系统为主要作用部位,以呼出气末麻醉药浓度监测临床效应(如对伤害性刺激的不动反应)。
  • 吸入性药物具有独特的药代动力学、极少的代谢和独特的恢复特征。
  • 国际上有两种吸入镇静给药系统,均由微型挥发器、输送控制器和监测器组成,其中一个系统目前正在美国接受评估。
  • 给药系统有各自的安全考量,如潮气量限制。

证据类型、等级与局限

  • 证据类型:综述(纳入原始研究、综述、评论及指南)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 综述结论认为挥发性麻醉药可用作ICU镇静剂。
  • 使用吸入镇静给药系统时需注意其安全考量,如潮气量限制。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Volatile anesthetics (VAs) are gaining renewed interest as a sedation strategy in the intensive care, offering an alternative to traditional IV agents. VAs provide several pharmacologic advantages, including rapid onset and offset, minimal systemic metabolism, and favorable recovery profiles. Advances in delivery systems enabled the safe and practical administration of volatile agents in the ICU. Thus, we aimed to describe the pharmacology and safety aspects of inhaled agents as well as the systems designed to deliver VAs in the ICU.

DATA SOURCES: Relevant literature was identified through PubMed and MEDLINE databases.

STUDY SELECTION: Original research, review articles, commentaries, and guidelines addressing safety, efficacy, and use of VAs in adult ICU patients were included.

DATA EXTRACTION: Studies were reviewed by the authors, with key findings summarized and organized by pharmacologic properties, delivery systems, and safety domains.

DATA SYNTHESIS: VAs are halogenated hydrocarbons whose mechanism of action is not fully understood. Although the CNS is the primary site of action, the end-tidal concentration of exhaled anesthetic is used to monitor clinical effects such as immobility to a noxious stimulus. Inhaled agents have unique pharmacokinetics, minimal metabolisms, and distinct recovery. The side effect profile is also unique, with malignant hyperthermia being the most feared, yet rare complication. Two systems for inhalational sedation delivery are available internationally, with one currently under evaluation in the United States. The systems are composed of a miniature vaporizer, delivery controller, and a monitor. The systems have distinct safety considerations, such as tidal volume limits.

CONCLUSIONS: VAs can be used as sedative agents in the ICU. This article comprehensively reviews the pharmacology of VAs along with their safety profile and describes the structure and function of miniature vaporizers currently available on the world market.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Kopańczyk R, Wieruszewski PM, Yin W, et al. Volatile Anesthetics: A Comprehensive Review of Pharmacology, Delivery Systems, and Safety Considerations for ICU Practitioners. Crit Care Med. 2026. PMID: 41556744. doi:10.1097/CCM.0000000000007042

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。